MET and non-small cell lung carcinoma: However, the molecular mechanisms of these c-Met activities in NSCLC cells remain unclear, especially its epigenetic underlying molecular mechanism, thus forming a basis for continued exploration of the pharmacologic and molecular targetability, as well as the epigenetic modulation of MET signaling in NSCLC patients.